首页> 美国卫生研究院文献>Oncotarget >NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand
【2h】

NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand

机译:新西兰北岛和南岛患者的转移性黑色素瘤的NRAS和EPHB6突变率不同

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Melanoma, the most aggressive skin cancer type, is responsible for 75% of skin cancer related deaths worldwide. Given that New Zealand (NZ) has the world's highest melanoma incidence, we sought to determine the frequency of mutations in NZ melanomas in recurrently mutated genes. NZ melanomas were from localities distributed between North (35°S-42°S) and South Islands (41°S-47°S). A total of 529 melanomas were analyzed for BRAF exon 15 mutations by Sanger sequencing, and also by Sequenom MelaCarta MassARRAY. While, a relatively low incidence of BRAFV600E mutations (23.4%) was observed overall in NZ melanomas, the incidence of NRAS mutations in South Island melanomas was high compared to North Island melanomas (38.3% vs. 21.9%, P=0.0005), and to The Cancer Genome Atlas database (TCGA) (38.3% vs. 22%, P=0.0004). In contrast, the incidence of EPHB6G404S mutations was 0% in South Island melanomas, and was 7.8% in North Island (P=0.0002). Overall, these data suggest that melanomas from geographically different regions in NZ have markedly different mutation frequencies, in particular in the NRAS and EPHB6 genes, when compared to TCGA or other populations. These data have implications for the causation and treatment of malignant melanoma in NZ.
机译:黑色素瘤是最具侵略性的皮肤癌类型,占全球皮肤癌相关死亡的75%。鉴于新西兰(NZ)黑色素瘤的发病率是世界上最高的,因此我们试图确定复发性突变基因中NZ黑色素瘤的突变频率。 NZ黑色素瘤来自北部(35°S-42°S)和南岛(41°S-47°S)之间分布的地区。通过Sanger测序以及Sequenom MelaCarta MassARRAY分析了总共529个黑色素瘤的BRAF外显子15突变。虽然在新西兰黑素瘤中总体观察到BRAF V600E 突变的发生率相对较低(23.4%),但与北岛黑素瘤相比,南岛黑素瘤中NRAS突变的发生率较高(38.3%vs. 21.9) %,P = 0.0005)和癌症基因组图谱数据库(TCGA)(38.3%vs. 22%,P = 0.0004)。相比之下,EPHB6 G404S 突变在南岛黑色素瘤中的发生率为0%,在北岛黑色素瘤中的发生率为7.8%(P = 0.0002)。总体而言,这些数据表明,与TCGA或其他人群相比,来自新西兰不同地理区域的黑色素瘤具有明显不同的突变频率,尤其是在NRAS和EPHB6基因中。这些数据对新西兰恶性黑色素瘤的病因和治疗具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号